BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32433789)

  • 61. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?
    Cheah CY; Seymour JF
    Curr Oncol Rep; 2015 Jun; 17(6):25. PubMed ID: 25912004
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
    Fukuhara S; Watanabe T; Munakata W; Mori M; Maruyama D; Kim SW; Kobayashi Y; Taniguchi H; Maeshima AM; Tanosaki R; Matsuno Y; Tobinai K
    Eur J Haematol; 2011 Nov; 87(5):434-40. PubMed ID: 21740461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
    Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Primary central nervous system lymphoma as a neurosurgical problem.
    Szczepanek D; Wąsik-Szczepanek E; Stoma F; Sokołowska B; Trojanowski T
    Neurol Neurochir Pol; 2017; 51(4):319-323. PubMed ID: 28476199
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 68. Prevention of CNS relapse in diffuse large B-cell lymphoma.
    Kridel R; Dietrich PY
    Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
    Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
    Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
    [No Abstract]   [Full Text] [Related]  

  • 70. Relapse in stage I(E) diffuse large B-cell lymphoma.
    Nijland M; Boslooper K; van Imhoff G; Kibbelaar R; Joosten P; Storm H; van Roon EN; Diepstra A; Kluin-Nelemans HC; Hoogendoorn M
    Hematol Oncol; 2018 Apr; 36(2):416-421. PubMed ID: 29083044
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Diffuse large B-cell lymphoma of the testis relapsed 16 years after achieving complete response].
    Nagasaka I; Mitsui T; Ishizaki T; Koiso H; Yokohama A; Saitoh T; Hirato J; Igarashi T; Kojima M; Tsukamoto N; Nojima Y; Murakami H; Handa H
    Rinsho Ketsueki; 2015 Dec; 56(12):2447-51. PubMed ID: 26725353
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Secondary central nervous system lymphoma: risk factors and prophylaxis.
    Montoto S; Lister TA
    Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
    Qualls D; Abramson JS
    Haematologica; 2019 Jan; 104(1):25-34. PubMed ID: 30573511
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
    Mitrovic Z; Bast M; Bierman PJ; Bociek RG; Vose JM; Chan WC; Armitage JO
    Br J Haematol; 2012 May; 157(3):401-3. PubMed ID: 22224728
    [No Abstract]   [Full Text] [Related]  

  • 76. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival.
    Zhang T; Zhao H; Cui Z; Xu H; Liu X; Wu Y; Li Y; Sun S; Wang P; Wang Y; Shi X
    Hematology; 2020 Dec; 25(1):203-210. PubMed ID: 32476626
    [No Abstract]   [Full Text] [Related]  

  • 77. Letter to the Editor. The place of brain biopsy in patients with presumed CNS relapse of systemic lymphoma.
    Mathon B; Amelot A
    J Neurosurg; 2021 Nov; 136(3):933-934. PubMed ID: 34740196
    [No Abstract]   [Full Text] [Related]  

  • 78. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
    Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
    Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
    Klanova M; Sehn LH; Bence-Bruckler I; Cavallo F; Jin J; Martelli M; Stewart D; Vitolo U; Zaja F; Zhang Q; Mattiello F; Sellam G; Punnoose EA; Szafer-Glusman E; Bolen CR; Oestergaard MZ; Fingerle-Rowson GR; Nielsen T; Trneny M
    Blood; 2019 Feb; 133(9):919-926. PubMed ID: 30617197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.